Literature DB >> 19089402

[Role of lymph node dissection in prostate cancer].

T Schlomm1, C Börgermann, H Heinzer, H Rübben, H Huland, M Graefen.   

Abstract

We present a comprehensive literature review and critical discussion of the diagnostic and therapeutic value of lymph node dissection in prostate cancer. Lymph node dissection is currently the most reliable staging procedure for detecting lymph node metastases in prostate cancer. Accuracy increases with the extent of the procedure. Overall, in patients with positive lymph nodes after radical prostatectomy and lymph node dissection, a favorable long-time cancer-specific survival can be observed. These data seem to be independent of the extent of the lymph node dissection and also independent of the administration of adjuvant therapy. It can be suspected that patients with lymph node metastases present different prognostic groups based on the extent of lymph node involvement. However, these risk groups might reflect only a lead-time bias, so the therapeutic value of lymph node dissection remains unclear. In conclusion, the therapeutic value of lymph node dissection in prostate cancer must be sufficiently evaluated in prospective clinical trials. Each patient should be individually counseled regarding his individual tumor features and the use of statistical prognostic tools such as nomograms.

Entities:  

Mesh:

Year:  2009        PMID: 19089402     DOI: 10.1007/s00120-008-1758-6

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  35 in total

1.  Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?

Authors:  Pia Bader; Fiona C Burkhard; Regula Markwalder; Urs E Studer
Journal:  J Urol       Date:  2003-03       Impact factor: 7.450

2.  Editorial comment on: high provider volume is associated with lower rate of secondary therapies after definitive radiotherapy for localized prostate cancer.

Authors:  Mack Roach
Journal:  Eur Urol       Date:  2007-11-06       Impact factor: 20.096

3.  How many lymphadenectomies does it take to cure one patient?

Authors:  Eric A Klein; Michael Kattan; Andrew Stephenson; Andrew Vickers
Journal:  Eur Urol       Date:  2007-09-19       Impact factor: 20.096

4.  Validation of a nomogram predicting the probability of lymph node invasion among patients undergoing radical prostatectomy and an extended pelvic lymphadenectomy.

Authors:  Alberto Briganti; Felix K-H Chun; Andrea Salonia; Giuseppe Zanni; Vincenzo Scattoni; Luc Valiquette; Patrizio Rigatti; Francesco Montorsi; Pierre I Karakiewicz
Journal:  Eur Urol       Date:  2006-02-17       Impact factor: 20.096

5.  Guideline for the management of clinically localized prostate cancer: 2007 update.

Authors:  Ian Thompson; James Brantley Thrasher; Gunnar Aus; Arthur L Burnett; Edith D Canby-Hagino; Michael S Cookson; Anthony V D'Amico; Roger R Dmochowski; David T Eton; Jeffrey D Forman; S Larry Goldenberg; Javier Hernandez; Celestia S Higano; Stephen R Kraus; Judd W Moul; Catherine M Tangen
Journal:  J Urol       Date:  2007-06       Impact factor: 7.450

6.  Prostate cancer and the Will Rogers phenomenon.

Authors:  Peter C Albertsen; James A Hanley; George H Barrows; David F Penson; Pam D H Kowalczyk; M Melinda Sanders; Judith Fine
Journal:  J Natl Cancer Inst       Date:  2005-09-07       Impact factor: 13.506

7.  Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer.

Authors:  Alberto Briganti; Felix K-H Chun; Andrea Salonia; Nazareno Suardi; Andrea Gallina; Luigi Filippo Da Pozzo; Marco Roscigno; Giuseppe Zanni; Luc Valiquette; Patrizio Rigatti; Francesco Montorsi; Pierre I Karakiewicz
Journal:  Eur Urol       Date:  2006-08-31       Impact factor: 20.096

8.  The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era.

Authors:  David S DiMarco; Horst Zincke; Thomas J Sebo; Jeffrey Slezak; Erik J Bergstralh; Michael L Blute
Journal:  J Urol       Date:  2005-04       Impact factor: 7.450

9.  Assessment of pathological prostate cancer characteristics in men with favorable biopsy features on predominantly sextant biopsy.

Authors:  Felix K-H Chun; Nazareno Suardi; Umberto Capitanio; Claudio Jeldres; Sascha Ahyai; Markus Graefen; Alexander Haese; Thomas Steuber; Andreas Erbersdobler; Francesco Montorsi; Hartwig Huland; Pierre I Karakiewicz
Journal:  Eur Urol       Date:  2008-05-15       Impact factor: 20.096

10.  Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy.

Authors:  Martin C Schumacher; Fiona C Burkhard; George N Thalmann; Achim Fleischmann; Urs E Studer
Journal:  Eur Urol       Date:  2008-05-21       Impact factor: 20.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.